Systematic Review and Meta-Analysis of Selected Toxicities of Approved ALK Inhibitors in Metastatic Non-Small Cell Lung Cancer

Oncotarget - United States
doi 10.18632/oncotarget.25154
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Tackling ALK in Non-Small Cell Lung Cancer: The Role of Novel Inhibitors

Translational Lung Cancer Research
Oncology
2016English

Efficacy of EGFR-TKIs With or Without Angiogenesis Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Journal of Cancer
Oncology
2020English

New Options in the Management of Intractable ALK(+) Metastatic Non-Small-Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2014English

Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

PLoS ONE
Multidisciplinary
2011English

Clinicopathological Significance of DAPK Promoter Methylation in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Cancer Management and Research
Oncology
2018English

Prophylactic Cranial Irradiation in Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Brigatinib for ALK-positive Metastatic Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2019English

Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2012English

P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy